Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, +18

New England Journal of Medicine

Azacitidine in the management of patients with myelodysplastic syndromes

Cyrus Khan, Neeta Pathe, Salman Fazal, +2

Therapeutic Advances in Hematology

Hematological MalignancyOncologyMedicineAplastic AnemiaMixed-phenotype Acute Leukemia +8

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Martin Hutchings, Carmelo Carlo‐Stella, Franck Morschhauser, +17

Blood

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, +17

Journal of Clinical Oncology

ImmunologyPrior TherapiesPathologyImmunodominanceImmunoediting +19

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, John M. Burke, Bruce D. Cheson, +15

Blood

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Anas Younes, John M. Burke, Bruce D. Cheson, +15

Blood Advances

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, +17

Blood

Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia

Santhosh Sadashiv, Christie Hilton, Cyrus Khan, +6

Cancer Medicine

Hematological MalignancyOncologyElderly PatientsMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia +9

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Martin Hutchings, Carmelo Carlo‐Stella, Franck Morschhauser, +17

Blood

Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome

Palash Asawa, Urwat Til Vusqa, Cyrus Khan, +2

Anticancer Research